Lisa Harder‐Rauschenberger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lisa Harder‐Rauschenberger has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Chi Wang Ip
Department of Neurology, University Hospital Würzburg, Würzburg, Germany
4 shared publications - Jens Volkmann
Department of Neurology, University Hospital Würzburg, Würzburg, Germany
3 shared publications Chi Wang Ip
Department of Neurology, University Hospital Würzburg, Josef-Schneider-Straße 2, 97080, Würzburg, Germany
2 shared publications- Philip Tovote
Institute of Clinical Neurobiology, University Hospital Wuerzburg, Wuerzburg, Germany
2 shared publications - Aet O'Leary
Division of Neuropsychopharmacology, Institute of Chemistry, University of Tartu, Tartu, Estonia
1 shared publication - Alain Ndayisaba
Department of Neurology, Mass General Brigham, Harvard Medical School, Boston, MA, 02115
1 shared publication
Latest Publications
- Open Access
- 5 November 2026
- Published by Wiley in Movement Disorders
Skin Seed Amplification Assay Differentiates Multiple System Atrophy from Parkinson's Disease
Background: Misdiagnoses of multiple system atrophy (MSA) and Parkinson's disease (PD) remain common. Objective: The objective of the study was to develop a skin α‐synuclein seed amplification assay (αSyn‐SAA) for detecting pathological α‐synuclein and distinguishing MSA from PD. Methods: In this blinded, cross‐sectional study, 308 skin biopsies from 117 participants were analyzed using a standardized thioflavin T fluorescence‐based αSyn‐SAA protocol. The cohort included 42 PD, 31 MSA, 30 controls, and 14 progressive supranuclear palsy (PSP) cases. Kinetic parameters were analyzed to differentiate PD from MSA, and matched skin cerebrospinal fluid (CSF)/magnetic resonance imaging (MRI) analyses were performed. Assay thresholds were predefined using brain lysates from neuropathologically confirmed cases. Fibril morphology from amplified skin samples was compared to postmortem brain using proteinase K digestion and electron microscopy. Results: αSyn‐SAA detected synucleinopathy (PD or MSA) with 82.2% sensitivity and 90% specificity versus controls. Receiver operating characteristic (ROC) analysis showed that maximum fluorescence ( F max , area under the curve [AUC] = 0.93) and lag time (AUC = 0.91) distinguished PD from MSA at the biopsy level. SAA positivity correlated with rapid eye movement (REM) sleep behavior disorder (RBD) in both disorders. Among SAA‐positive cases, the 50% mean F max cutoff correctly classified the underlying synucleinopathy in 81.7% of cases (49 of 60). Disease‐specific kinetic and structural signatures were reproducible across laboratories and αSyn substrate batches and were supported by concordant findings in a subset of skin samples matched to CSF, MRI data, and postmortem brain tissue. Conclusion: Skin αSyn‐SAA detects pathological α‐synuclein in living patients with high accuracy and distinguishes MSA from PD based on assay kinetics and fibril strain properties, supporting its potential as a biomarker to distinguish among synucleinopathies. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 5 November 2026
- Published by Wiley in Movement Disorders
Open AccessSkin Seed Amplification Assay Differentiates Multiple System Atrophy from Parkinson's Disease
Background: Misdiagnoses of multiple system atrophy (MSA) and Parkinson's disease (PD) remain common. Objective: The objective of the study was to develop a skin α‐synuclein seed amplification assay (αSyn‐SAA) for detecting pathological α‐synuclein and distinguishing MSA from PD. Methods: In this blinded, cross‐sectional study, 308 skin biopsies from 117 participants were analyzed using a standardized thioflavin T fluorescence‐based αSyn‐SAA protocol. The cohort included 42 PD, 31 MSA, 30 controls, and 14 progressive supranuclear palsy (PSP) cases. Kinetic parameters were analyzed to differentiate PD from MSA, and matched skin cerebrospinal fluid (CSF)/magnetic resonance imaging (MRI) analyses were performed. Assay thresholds were predefined using brain lysates from neuropathologically confirmed cases. Fibril morphology from amplified skin samples was compared to postmortem brain using proteinase K digestion and electron microscopy. Results: αSyn‐SAA detected synucleinopathy (PD or MSA) with 82.2% sensitivity and 90% specificity versus controls. Receiver operating characteristic (ROC) analysis showed that maximum fluorescence ( F max , area under the curve [AUC] = 0.93) and lag time (AUC = 0.91) distinguished PD from MSA at the biopsy level. SAA positivity correlated with rapid eye movement (REM) sleep behavior disorder (RBD) in both disorders. Among SAA‐positive cases, the 50% mean F max cutoff correctly classified the underlying synucleinopathy in 81.7% of cases (49 of 60). Disease‐specific kinetic and structural signatures were reproducible across laboratories and αSyn substrate batches and were supported by concordant findings in a subset of skin samples matched to CSF, MRI data, and postmortem brain tissue. Conclusion: Skin αSyn‐SAA detects pathological α‐synuclein in living patients with high accuracy and distinguishes MSA from PD based on assay kinetics and fibril strain properties, supporting its potential as a biomarker to distinguish among synucleinopathies. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 29 December 2025
- Published by Wiley in Movement Disorders
- Vol. 41 (2) , 553-554
Reply to: “Moving Forward in Movement Disorders: The Need for Studies on Environmental Triggers”
- 29 December 2025
- Published by Wiley in Movement Disorders
- Vol. 41 (2) , 553-554
Open AccessReply to: “Moving Forward in Movement Disorders: The Need for Studies on Environmental Triggers”
- Open Access
- 14 October 2025
- Published by Wiley in Movement Disorders
- Vol. 41 (1) , 27-39
The Second Hit Hypothesis in Animal and Human Dystonia: The Role of Peripheral Nerve Trauma and Spinal Cord Injury
Dystonia is a complex movement disorder characterized by involuntary muscle contractions and abnormal postures. Although genetic factors have been implicated in dystonia pathogenesis, recent evidence suggests that additional environmental triggers, referred to as the second hit, may play a significant role in the development and progression of the disease. A remarkably low penetrance in some of the monogenic forms of dystonia supports the need for additional triggers to unmask the phenotype. Given that dystonia has been reported to develop after traumatic events, this review explores the second hit hypothesis in animal models of dystonia and its potential relevance to human dystonia, with particular emphasis on the role of nerve and spinal cord injuries. These injuries trigger significant peripheral changes and profound brain and spinal cord circuit alterations, which require a healthy immune system and functional and structural plasticity responses. We discuss how nerve and spinal cord injuries initiate these key pathomechanistic processes, including neuroinflammation and the reorganization of the central sensorimotor network, which entails adaptive modifications in neural pathways to compensate for the injury. We further highlight future challenges and potential therapeutic implications of nerve and spinal cord injury–induced dystonia. Understanding the interplay between nerve injury, spinal cord injury, neuroinflammation, and dystonia may pave the way for novel therapeutic strategies targeting these factors. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 14 October 2025
- Published by Wiley in Movement Disorders
- Vol. 41 (1) , 27-39
Open AccessThe Second Hit Hypothesis in Animal and Human Dystonia: The Role of Peripheral Nerve Trauma and Spinal Cord Injury
Dystonia is a complex movement disorder characterized by involuntary muscle contractions and abnormal postures. Although genetic factors have been implicated in dystonia pathogenesis, recent evidence suggests that additional environmental triggers, referred to as the second hit, may play a significant role in the development and progression of the disease. A remarkably low penetrance in some of the monogenic forms of dystonia supports the need for additional triggers to unmask the phenotype. Given that dystonia has been reported to develop after traumatic events, this review explores the second hit hypothesis in animal models of dystonia and its potential relevance to human dystonia, with particular emphasis on the role of nerve and spinal cord injuries. These injuries trigger significant peripheral changes and profound brain and spinal cord circuit alterations, which require a healthy immune system and functional and structural plasticity responses. We discuss how nerve and spinal cord injuries initiate these key pathomechanistic processes, including neuroinflammation and the reorganization of the central sensorimotor network, which entails adaptive modifications in neural pathways to compensate for the injury. We further highlight future challenges and potential therapeutic implications of nerve and spinal cord injury–induced dystonia. Understanding the interplay between nerve injury, spinal cord injury, neuroinflammation, and dystonia may pave the way for novel therapeutic strategies targeting these factors. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
- 28 July 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 142, 107975
Validation of clinical ratings of cervical dystonia using computer-generated avatars
- 28 July 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 142, 107975
Open AccessValidation of clinical ratings of cervical dystonia using computer-generated avatars
- Open Access
- 19 February 2024
- Published by Frontiers Media SA in Dystonia
- Vol. 3, 11793
Unraveling dystonia circuitry in rodent models using novel neuromodulation techniques
Dystonia is a network disorder presumed to result from abnormalities in multiple brain regions and in multiple cell populations. The specific pathomechanisms affecting the motor circuits in dystonia are, however, still largely unclear. Animal models for dystonia have long been used to advance our understanding on how specific brain regions and cell populations are involved in dystonia symptomatogenesis. Lesioning, pharmacological modulation and electrical stimulation paradigms were able to highlight that both the basal ganglia and the cerebellum are pathologically altered in these animal models for dystonia. Techniques such as optogenetics and chemogenetics now offer the opportunity for targeted modulation of brain regions and most importantly cell populations and circuits. This could not only allow for a better understanding of the dystonic brain, but potentially improve and expand treatment options. In hopes that the insights from these neuromodulation techniques will eventually translate into therapies, we aim to summarize and critically discuss the findings from different in vivo approaches used to dissect the network dysfunctions underlying dystonia.
- 19 February 2024
- Published by Frontiers Media SA in Dystonia
- Vol. 3, 11793
Open AccessUnraveling dystonia circuitry in rodent models using novel neuromodulation techniques
Dystonia is a network disorder presumed to result from abnormalities in multiple brain regions and in multiple cell populations. The specific pathomechanisms affecting the motor circuits in dystonia are, however, still largely unclear. Animal models for dystonia have long been used to advance our understanding on how specific brain regions and cell populations are involved in dystonia symptomatogenesis. Lesioning, pharmacological modulation and electrical stimulation paradigms were able to highlight that both the basal ganglia and the cerebellum are pathologically altered in these animal models for dystonia. Techniques such as optogenetics and chemogenetics now offer the opportunity for targeted modulation of brain regions and most importantly cell populations and circuits. This could not only allow for a better understanding of the dystonic brain, but potentially improve and expand treatment options. In hopes that the insights from these neuromodulation techniques will eventually translate into therapies, we aim to summarize and critically discuss the findings from different in vivo approaches used to dissect the network dysfunctions underlying dystonia.
- Open Access
- 1 July 2021
- Published by Elsevier in Neurobiology of Disease
- Vol. 154, 105337
The evolution of dystonia-like movements in TOR1A rats after transient nerve injury is accompanied by dopaminergic dysregulation and abnormal oscillatory activity of a central motor network
- 1 July 2021
- Published by Elsevier in Neurobiology of Disease
- Vol. 154, 105337
Open AccessThe evolution of dystonia-like movements in TOR1A rats after transient nerve injury is accompanied by dopaminergic dysregulation and abnormal oscillatory activity of a central motor network
- Open Access
- 1 January 2020
- Published by Elsevier in Experimental Neurology
- Vol. 323, 113109
Striatal dopaminergic dysregulation and dystonia-like movements induced by sensorimotor stress in a pharmacological mouse model of rapid-onset dystonia-parkinsonism
- 1 January 2020
- Published by Elsevier in Experimental Neurology
- Vol. 323, 113109
Open AccessStriatal dopaminergic dysregulation and dystonia-like movements induced by sensorimotor stress in a pharmacological mouse model of rapid-onset dystonia-parkinsonism